Education
About Us
Working with TipRanks
Follow Us
Immuron Limited (DE:ANW)
FRANKFURT:ANW
ANW Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EST
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€6.17M
Enterprise Value-€2.00M
Total Cash (Recent Filing)€10.00M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Aug 28, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding326,653,600
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.75
Price to Sales (P/S)1.93
P/FCF Ratio-2.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€5.63M
Bulls Say, Bears Say
Bulls Say
Commercial Product (Travelan)Having Travelan as a marketed, consumer-facing product gives Immuron a real-world revenue stream and distribution relationships. A commercial product lowers binary clinical risk, supplies customer/market feedback, and provides a basis for incremental sales and scaling independent of approval outcomes for pipeline drugs.
Revenue Growth TrendConsistent top-line growth (double-digit year) signals underlying demand for Immuron’s offerings and supports the case for expanding commercial activity. Sustained revenue increases improve the company’s ability to justify further investment in trials and commercialization, aiding medium-term viability if margins improve.
Conservative LeverageVery low debt reduces interest burden and insolvency risk, preserving balance-sheet flexibility. For a cash-burning biotech, conservative leverage means more optionality to raise capital or partner programs without heavy fixed costs, which is valuable across multiple financing cycles.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flow constrains the company’s ability to self-fund clinical development and commercial expansion. Structural cash burn increases dependency on external financing or partnerships, which can dilute equity or delay programs and limit strategic flexibility over the medium term.
Ongoing UnprofitabilitySustained negative profitability indicates operations are not yet generating returns and limits reinvestment capacity. Ongoing losses heighten reliance on capital markets or partners to progress pipeline assets and can extend the timeline before shareholders see positive earnings, a structural headwind for long-term investors.
Very Small TeamA headcount of seven limits internal bandwidth for clinical programs, regulatory filings, and commercial rollouts. Reliance on a very small team increases execution and operational risk, often requiring external contractors or partners which can slow timelines and raise costs during critical development phases.
Immuron Limited News
ANW FAQ
What was Immuron Limited’s price range in the past 12 months?
Immuron Limited lowest stock price was €0.01 and its highest was €0.05 in the past 12 months.
What is Immuron Limited’s market cap?
Immuron Limited’s market cap is €6.17M.
When is Immuron Limited’s upcoming earnings report date?
Immuron Limited’s upcoming earnings report date is Aug 28, 2026 which is in 166 days.
How were Immuron Limited’s earnings last quarter?
Immuron Limited released its earnings results on Feb 25, 2026. The company reported -€0.004 earnings per share for the quarter, missing the consensus estimate of €0 by -€0.004.
Is Immuron Limited overvalued?
According to Wall Street analysts Immuron Limited’s price is currently Overvalued.
Does Immuron Limited pay dividends?
Immuron Limited does not currently pay dividends.
What is Immuron Limited’s EPS estimate?
Immuron Limited’s EPS estimate is 0.
How many shares outstanding does Immuron Limited have?
Immuron Limited has 326,653,600 shares outstanding.
What happened to Immuron Limited’s price movement after its last earnings report?
Immuron Limited reported an EPS of -€0.004 in its last earnings report, missing expectations of €0. Following the earnings report the stock price went up 15.385%.
Which hedge fund is a major shareholder of Immuron Limited?
Currently, no hedge funds are holding shares in DE:ANW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immuron Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:ANW Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.31%
12-Months-Change
Fundamentals
Return on Equity
-49.96%
Trailing 12-Months
Asset Growth
-41.64%
Trailing 12-Months
Company Description
Immuron Limited
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III registration trial to reduce the risk of contracting travelers' diarrhea in the United States, and Phase II field trial for Travelers' Diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in Phase I/IIa clinical trial for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Technical Analysis
Noxopharm Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Anatara Lifesciences Ltd
―
Neuroscientific Biopharmaceuticals Ltd.
―